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Executive Summary
A content analysis ofpharmaceutical product ads targeted toward pediatricians in the
professional mediawas conducted to determine the extent to which they were informative
as well as the quantity and types of information presented. The content analysis model
selected was based on previously published and widely implemented standards that have
been documented to support research propositions. The study analyzed 67 separate
products ads that were published in pediatrician-targeted journals during the first halfof
2002. The results indicate that each pharmaceutical product ad contains an abundance of
information (average = 5.1 cues) that may help in educating and Morming the physician.
Ads in support ofnewly launched products contained a higher number of information
cues per ad (6. 1). Distinct patterns of information content within the ads emerged. Most
notable was that 53% ofprescription drug ads were perceived to be overly weighted with
benefit information, in apparent defiance ofFDA regulations. In addition, while over
95% ofprescription and OTC ads illustrated product benefits and characteristics, only
71% identified the disease or condition forwhich the product is indicated. Ads were
typically found not to contain much information on dosing or treatment directives.
Surprisingly, only 35% ofads contained any scientific information in support of the
product, whereas 52% contained emotional cues. These data suggest that the approach
used by pharmaceutical companies to communicate with physicians is not sufficiently
rational. It appears that the advertising agencies may be having a more profound
influence on advertising copy than is expected considering the professional status of the
targeted audience.
Introduction
Physicians are exposed to pharmaceutical promotion in the form ofDirect To
Consumer (DTC) advertising, sales force detailing, continuing medical education and in
the professional media (1). Therefore, today's pharmaceutical product manager is
challenged with effectively allocating funds across the entire gamut ofpromotional
vehicles, while maintaining stringent budgetary goals. Whereas, investment in
pharmaceutical promotion increased from $9.2 billion in 1996 to $15.7 billion in 2000,
the bulk of this increased investment has occurred inDTC, and the expense ofpromotion
to the physician has declined (2). Thus, the advent ofDTC has profoundly impacted the
modes used by pharmaceutical companies to advertise products to their customers.
There is much debate over the motives behind pharmaceuticalDTC advertising
(3). Although proponents ofDTC argue that such advertising programs involve patients
directly in their own healthcare, the potential impact on the standard ofhealthcare that
patients ultimately receive has yet to be fully determined. Studies have shown that in
today's constrained managed care environment, physicians might be prompted to comply
by prescribing what consumers demand rather than take the time and effort (and cost) to
complete a full diagnosis (3, 4). There is also the danger that in a blinkered quest for
profits, pharmaceutical companies might even exclude the physician altogether in the
communication process. One example involves the anti-cholesterol drug, PravachoL
which targeted only consumers (5). The result was that physicians preferentially
prescribed the competing brand Lipitor (5). Thus, the prevailing message to product
managers is one ofa balanced promotional program that acknowledges the physician as
the healthcare "gatekeeper" and incorporates physician-targeted communication as a vital
partner to DTC.
With respect to the logic behind a balanced promotional campaign, it has been
quantified that dollars have been diverted away from professional journals over the past
ten years in favor of increased sales forces, educational programs and most notably DTC
advertising (6). In 2000 - 2001, spending by pharmaceutical companies on journal
advertising declined by 13% (7) while expenditures on sales forces has grown by 16%
(6). This escalation of inter-company competition for valuable time with the physician
dictates that sales representatives invariably end up at the receptionist's window or
receive only minutes of face time with the doctor (8). Such limited time compromises the
information flow to the physician and moreover, compels the physician to acquire
important information on drugs from alternate sources.
Thus, advertisements in the professional media may play a more imperative role
in the communication process between pharmaceutical company and physician than ever
before. Indeed, a 2001 independent study showed journal advertising to provide a greater
return on investment than either sales force detailing, DTC, ormedical education (9). In
addition to being cost-effective, journal advertising is also described as a preferred source
of information for physicians, presented in a user-friendly format and with information
assimilated at times determined by the physician (6, 15). But, alternative viewpoints
suggest that ifphysicians receive all oftheir information about drugs from advertising
then health care may be compromised (1). These apparently contrasting viewpoints
highlight the need to better comprehend the informational content currently provided by
pharmaceutical companies to physicians through the professional media.
This study seeks to fill the void in the literature regarding the content of
pharmaceutical advertisements to physicians. As such, the study is designed to help
guide product managers as they develop advertisements for the professional media. In
order to perform a manageable research study, only those ads targeted toward a subgroup
ofphysicians, pediatricians, were used as a paradigm for medical advertising as awhole.
Pediatric Journals are easily identifiable by title and thus represent an accessible vehicle
inwhich to identify patterns ofpharmaceutical advertising to physicians.
Research Objectives and Propositions
The objective of this study is to investigate the approaches used to advertise
healthcare products to pediatricians as a paradigm for pharmaceutical promotional
practices to physicians overall. While there is a paucity ofpublished content analyses of
pharmaceutical product advertisements targeted toward themedical professional, there is
an abundance ofresearch dedicated toward consumer advertising using the printed media.
Typically, research models were developed from a classification system for advertising
information cues based upon 14 criteria contained within an ad that facilitated intelligent
choices from among alternatives (13). Studies were geared, for example, toward
comparing the information content between U.S. and Japanese or Indian magazine
articles (11, 12). Analysis ofpharmaceutical product ads directed toward consumers has
investigated specific characteristics relating to both disease state and product including
(10):
Market size
Drug usage
Side effects
Lifecycle stage
While these criteriawere developed specifically for consumer advertising, the
basic tenets ofthe models serve as the foundation for this analysis. Thus, the impact of
influencing factors such as drug usage, side effects and product lifecycle will be analyzed
in association with specific informational cues to discern patterns ofcontent within and
between ads. In addition, the presentation of the ad will be characterized from a rational
and emotional standpoint to determine the mode ofcommunication ofthe message to the
audience. The influencing factors deemed most relevant to pharmaceutical product ads
formed the basis for the hypothesis development used in this study. Consequently, these
factor are discussed in more detail below.
Prescription Drugs
Pharmaceutical product advertisements in the professional media fall into 2
categories, those that are available only by prescription and those that are available over-
the-counter (OTC). In prescription advertisements wherein claims are made regarding
the products use or effectiveness, the Food & Drug Administration statutory requirements
(21 CFR 202.1) mandates ofa Brief Summary ofProduct Characteristics that provides
detailed information about the drug, its dosage, administration and contraindications.
This BriefSummary must also contain clinical data on the drug's efficacy and report any
adverse reactions that may occur after administration. Typically, the BriefSummary is
provided either adjacent to the actual ad or on the following page.
There is a substantial return required for an investment in advertising.
Consequently, there is an expectation that the majority ofproduct ads support
prescription drugs that are typically patent protected and thus can command higher
prices. In contrast, OTC products are speculated to be commodities and consequently
less advertised. Because of these differences, potential exists for differential patterns of
informational content between prescription and OTC products.
HI: Ads to physicians are more likely to be prescription (Rule for judgment:
acceptHI if>50%)
Benefits and Risks
For prescription drugs, there is an FDA requirement that the body ofan
advertisement contains a "Fair Balance" ofa drug's benefits and risks. The requirements
indicate that copy in favor of the product should be approximately balanced by
appropriate information on the safety and risks associated with the product. The statutory
requirement 21 CFR 202. 1(e)(5) states that both drug benefit and risk information be
presented in comparable depth and detail. Thus, there is an expectation that prescription
advertisements do contain such fair balance in accordance with FDA guidelines. This
study will test whether ads are perceived to be fairly balanced by the reader, and as such
will investigate the ethical obligations that pharmaceutical companies adhere to in
communicating with physicians. A high level for the judgment was set because majority
conformity is expected due to FDA regulations.
H2: Prescription Ads contain fairly balanced statements of benefits and risk
(Rule for judgment: accept H2 if>80%)
Stage ofProduct Lifecycle
One explanation for the recent decline in advertising expenditures in the medical
media is the lack ofnew product introductions, and the corresponding decrease in the
advertising investment (7). Also, it has also been proposed that the advertising of
maintenance products has declined due to the number ofnew introductions (6).
Interestingly, new product launches may be advertised with discrete informational
content that positions the product with unique competitive advantages in order to take
market share from "lesser" drugs. It is recognized that such new products have larger
expense budgets and therefore can be advertised more comprehensively. The
advertisements for new products typically contain identifiers such as
"introducing"
or
"new." This study will quantify the proportion ofads that contain new products and in so
doing correlate them with any distinct informational cues.
H3: Many advertised products tend to be early in their life cycle (Rule for
judgment: accept H3 if>30%)
Informational Cues
The crux ofthe analysis is to understandwhether targeted pharmaceutical ads are
a viable source of information for pediatricians. The model was adapted from that
employed by Resnik and Stern (13, 14) to include 14 information cues such as product
characteristics, scientific data, safety, and treatment (Appendix 1). In the Resnik and
Sternmodel, ads were deemed to be informative if they contained just 1 ofthe selected
information cues (13, 14). At such a low stringency, it's not surprising that some reports
indicate that the proportion of informative consumer-targeted ads ranges between 75%
and 85% (1 1). It is proposed that the nature of the pharmaceutical business obligates
companies to provide a higher level of factual and beneficial information regarding their
products than is expected in consumer ads. This proposal is based upon the important
role that pharmaceutical companies play in health care delivery and due to the presence
of federal regulatory guidelines. Therefore, this analysis proposes to classify an ad as
informative only if it contains at least 4 of the selected information cues.
H4: The majority of product advertisements can be deemed as informative
(Rule for judgment: accept H4 if >50% of ads contain >4 information
criteria)
Disease Identification
Identification of the disease to be targeted by a particular drug might be an
important aspect ofthe informative process. On the other hand, pharmaceutical drugs
can be used "off-label" for the treatment ofdiseases other than those for which the drug is
specifically indicated. Thus pharmaceutical ads may purposely not identify the particular
disease for which the pharmaceutical is indicated thus facilitating "off-label
use"
resulting in a positive impact on corporate revenue.
HS: Ads to pediatricians identify the disease to be treated (Rule for
judgment: accept H5 if >50%)
Treatment Directives
An important component ofthe information delivery process for a pharmaceutical
ad might be to provide direction on the use of the drug, when to use the drug, or
regarding the type ofpatient in whom the drug can and should be used. Even with the
possibility that ads will not identify the disease to be treated, they nevertheless may
provide directions on the use ofthe drug. Moreover, there is potential for an interesting
dichotomy in that the disease may not be identified (i.e., rejection ofH5) but specific
direction on the drugs usage is provided (i.e., H6 is not rejected). In this scenario, the
data would be suggestive of ads being exquisitely designed to maximize profits even for
disease states in which the drug has not been indicated or otherwise not proven effective.
H6: Ads provide direction on the use of the drug (Rule for judgment: accept
H6if>50%)
Scientific Data
The goal ofthe pharmaceutical product manager is to inform the physician about
the qualities ofa drug and the impact it might have on the patient. Thus, product ads
targeted toward physicians might be expected to display a variety of scientific data
outlining the effectiveness ofthe drug in order that comparisons can be made to
competitor treatments. Moreover this question contributes to the determination of
whether physicians make decisions based upon rational scientific information or are
motivated by emotion. The original Resnik and Stern model focused on discerning
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company-sponsored data from independent research (13). While the potential for such
discriminationwas retained in the current model used in this study, information regarding
product efficacy data and scientific data in any formwas additionally collected.
H7: Scientific data is an important tool used to validate product benefits
(Rule for judgment: accept H7 if>50%)
Ad presentation: the role of emotion
It is well recognized that ads need to be oriented to the specific customer group in
order to be effective, and this basic marketing theory applies to healthcare professionals
(15). For example, information on symptom reliefwould be encouraged for physicians
while managed care officials might prefer demonstrations ofeconomic value. Various
factors can influence ad performance and these can be measured using ad recall studies.
The goal of the ad is twofold; 1) draw the attention of the physician and 2) motivate to
read and take action. However, market research indicates that very few ads are recalled
unaided, and few physicians can accurately describe the ad or its content (15, 16, 17).
Thus, to be successful an ad needs to get noticed, be easily assimilated, validate claims
and be remembered. Ofcentral importance to these objectives is the initial impact of the
headline that may influence the subsequent reading of the entire ad (27).
The theory to be investigated is that pharmaceutical companies appeal to
pediatricians based upon a rational approach to advertising (e.g., using scientific data)
rather than on emotional cues in the advertisement. This hypothesis is consistent with the
viewpoint ofDaniel Starch; "... the fact remains that superlative generalities are weak
arguments and far less convincing than a statement of
facts" (26). Thus, in this study the
questions were designed to investigate whether ads leverage product characteristics and
benefits rather than emotion to appeal to pediatricians. Emotion was assessed using a
series ofquestions regarding the headline and body copy, and more indirectly by virtue of
analysis ofthe creative artwork associated with the ad.
H8: Emotion stimulating cues have only a limited role in informing
physicians (Rule for judgment: accept H8 if<20%)
Research Methods
Content analysis was used to investigate the approaches used to advertise
healthcare products to physicians in the professional print media. The basic methodology
for content analysis includes objectivity, quantification and reliability as essential
components (18). Moreover, content analysis has been described as a useful method to
establishwhether patterns support research propositions with regard to the print media
(18, 19). Although such research has typically been targeted toward evaluation of
consumer advertising, thus mandating some reasonable adaptation prior to use as a tool to
evaluate pharmaceutical advertising.
In this study, advertisements targeted toward pediatricians, a discrete subgroup of
physicians, were specifically selected by utilizing sixwidely read pediatric journals. The
aim was to analyze all product advertisements in these journals from January to June
2002. This technique was implemented in order to remove the bias associated with
sample selection. The journals used were: Pediatrics, PediatricNews, Infectious
Diseases ofChildren, PediatricResearch, The Pediatric InfectiousDisease Journal, and
Archives ofPediatrics andAdolescentMedicine. These represent a cross section of
journals that range from peer-reviewed journals to magazines such as PediatricNews and
Infectious Diseases ofChildren that provide briefnews and commentary on clinical
developments. While this study is not designed to determine where physicians get their
information, it does provide information on the content ofads across the breadth of
journal types selected. As dictated by the models ofcontent analysis on which these
studies were based (18, 19), three specific criteriawere employed to ensure objectivity
and reliability: 1) establish clear rules and definitions, 2) provide judge training, and 3)
ensure judge independence and reliability.
Rules and Definitions
The analysiswas performed using a 1-page questionnaire that contained various
categories or information, the majority of responses to which were "yes or
no."Judges
were informed of the objectives of the study, and were asked to complete a questionnaire
on a sample pharmaceutical ad by way ofdiscussing each of the categories. The
questionnaire is supplied as Appendix 2.
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Judge Training
Judge training is important for both intra- and inter-judge reliability. Judges were
exposed to the operational definitions used in the questionnaire by way of an
approximately 1-hour presentation. This use ofa sample ad facilitated discussion of
concepts, definitions and potential conflicts. Particular attention was focused on
evaluation of the fair balance statements within the ad as well as enabling direction on
some ofthe more subjective categories, e.g., emotion.
Judge Independence and Reliability
Three independent judges were used for evaluating the content of67 distinct
advertisements. The judges possessed considerable experience across the healthcare
industry, and included a director ofpharmaceutical marketing, a family practice
physician and a rehabilitation counselor. Thus, theywere eminently capable of
comprehending the language associated with pharmaceutical product advertisements. To
ensure the accuracy ofconclusions resulting from the data analysis, it is imperative that
judges be able to make autonomous assessments ofthe content. Judgeswere selected to
be completely independent and were under no time constraint. In order to interpret
results with a high degree ofaccuracy, statistical measurements of the coefficient of
agreement were calculated prior to reconciliation (20). Reliability coefficients were
calculated for each coding category as well as for each product advertisement. OveraU,
the inter-judge reliability coefficient (Ir) was 0.88, a value that exceeds the Ir of0.70
suggested as an accuracy guideline (20). By advertisement, Ir ranged from 0.8 1 to 1 .00
(note: 3 ads were deleted from the analysis because of irreconcilable disagreements
between judges). By coding category, Ir ranged from 0.70 to 1.00 (Appendix 3). Where
necessary, discrepancies between judges were resolved by discussion and with this
author's input.
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Results and Implications
The results represent patterns in the advertising ofpharmaceutical products to
pediatricians for selected journals within the 6-months encompassing January to June of
2002. The focus on printed ads in the professional media recognizes the essential role of
journal advertising in the communication process between pharmaceutical company and
physician. In the 6 journals selected there were a total of41 1 product ads, ofwhich, 67
that were in support ofdifferent products from 31 companies were analyzed for
informational content. The frequency ofads varied significantly across the journals
(Appendix 4). The non peer-reviewed journals (Infectious Diseases ofChildren and
PediatricNews) included 78% of the total ads analyzed suggesting that advertisers think
these journals display a higher recall rating for the target audience versus the peer-
reviewed journals. There was no evidence from this study that pharmaceutical
companies prefer to advertise in the more prestigious peer-reviewed journals in the hopes
of enhancing brand value and creating additional demand for their products. However,
previous studies have documented that ads can be engineered to target specific customer
segments based upon the type of content (21). In this study, due to the disproportionate
distribution ofads across journal type, no statistically significant patterns in information
content of the ads were observed. Amore comprehensive analysis over a longer time
period might define such trends that relate informational content with journal type or
target audience.
The data collected from the study are presented in Appendix 3, which shows a
summary ofthe proportion ofanswers for each question in addition to the coefficient of
agreement for that category. The majority of ads were full page (78%) versus multi page
(17%) or halfpage (5%). Of the multi page ads, 55% advertised products that were also
described as new compared to an overall study average of29% (Appendix 3). This
significant increase is consistent with the large expense budgets that often accompany the
introduction ofnew products. Notable observations regarding the content ofthe ads are
described in detail below.
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Prescription Drugs
Amajor focus of this study was to identify patterns in informational content
between ads for prescription and non-prescription products. HI was developed based
primarily upon the assumption that prescription drugs command a higher price in the
marketplace relative to OTC drugs. Indeed, the data show that 65% ofthe product ads in
the sample were in support ofprescription products thusHI is not rejected (Appendix 3).
Benefits and Risks
For prescription drug ads, there is an expectation that ads conform to the FDA
regulations regarding fair balance. However, the data show, despite these federal
regulations, 53% ofprescription ads were perceived by the judges not to be fairly
balanced in benefits and risks (Appendix 3). Thus, H2 is rejected since > 20% of
prescription ads were found not to contain a fair balance of information. The coefficient
ofagreement (Ir) for this particular category was 0.94, and was therefore indicative of
nearly complete agreement on the assessment of the ads by each ofthe judges.
Specifically, these ads were biased in favor ofpresenting benefits over risks, and not one
single ad was judged to have presented risks in favor ofbenefits. This is an astounding
finding that warrants closer analysis ofads especiallywith reference to objective FDA
definitions and subjective reader perceptions. It is hard to believe that in an environment
of ever increasing FDA regulations that such advertising practices, whether they are real
or perceived, will be permitted to continue. That said, even though the FDAmust
approve all prescriptionDTC ads before publication, other studies have shown that 35%
ofads were perceived by the reader to be unbalanced in benefit and risk information (22).
Stage ofProduct Lifecycle
The rate ofapproval ofnew products has been declining since 2001, resulting in a
lower number ofnew product launches and a corresponding decrease in advertising
expenditures (6). As products proceed through their lifecycle, the available expenditures
decrease as growth is maximized and sustained until finally the product becomes an off-
patent commodity. Thus, lifecycle stage is an important factor in how a product is
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promoted. A significant proportion ofads were proposed to be in support ofnewly
launched products such that for H3, a rule for judgment of30% was implemented. In
reality, the data showed that 29% of the ads contained specific identifiers categorizing the
ad as new or recently introduced (Appendix 3). In view of the fact that < 30% ofads
were in support ofproducts described as "new", H3 is rejected. Nevertheless, since 29%
ofpharmaceutical ads are for new products, a more in depth analysis was performed on
this category with a view to identifying specific patterns in the content of these "new"
versus maintenance product ads.
Informational Cues
A priori, it is difficult to ascribe relevant criteria that meaningfully define an ad as
being informative. Resnik and Stern focused on the inclusion ofonly one informational
cue to conclude that the ad was informative but their studies were performed originally
on television (TV) ads to consumers (14). In their analysis, only 49% ofTV ads were
deemed to be informative based upon a single information cue. However, only 16% of
the ads contained 2 or more information cues and < 1% of ads had 3 informational cues
(14).
In applying these criteria to professional journal ads ofpharmaceutical products, a
series ofassumptions were made with regard to the quantity of information that might be
included in any ad. First, journals and magazines tend to be more informative than TV
ads (14). Second, it is intuitive that the goal of the pharmaceutical company is to inform
the physician about the products benefits versus competitors. Third, FDA regulations
dictate the inclusion ofcertain types and amounts of information. Thus, a higher
stringency level was set to determine whether pharmaceutical products ads were
informative.
The results of the study showed that 86% of the ads were found to contain at least
4 ofthe information cues. Moreover, 60% ofads contained at least 5, and 43% ofads
contained at least 6 of the information cues. Thus, H4 is not rejected since > 50% of the
ads contain at least 4 information cues. These numbers are particularly striking in the
face ofthe previously published literature that described patterns of consumer advertising
in which ads were largely non-informative (1 1, 12, 13, 14). The implication is that
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pharmaceutical product ads do in fact cater to the customer by providing information that
fulfills specific needs.
Prescription and OTC ads were directly compared for information content. Both
types ofad did not differ statistically with regard to the number of information cues
displayed (Appendix 5). Moreover, when compared to the overall study average of 5. 1
information cues per ad, prescription ads had 5. 1 cues and OTC ads had 5.2 cues.
However, in comparing those ads supporting new products versus maintenance products,
statistical differences were observed with regard to the average number of informational
cues (Appendix 6). Ads described as "new" contained an average of6.1 information cues
whereas maintenance products had only 4.7 cues per ad (p = 0.0049). The explanation
for such a difference might be based in the greater need for a comprehensive
informational program for new and unknown products relative to their well-known and
widely accepted maintenance counterparts.
Based upon the 14 criteria used to determinewhether an ad is informative, distinct
patterns of informational content were identified. As expected, the majority ofads
provided information on product characteristics and benefits (98 and 94%, respectively)
but other information cues were not as consistently presented (Appendix 3). It was also
apparent from the data that OTC products leverage product familiarity by way of
presenting the packaging of the brand within the ad. Compared to prescription drugs,
OTC products either highlighted the packaging or displayed a picture ofthe product to a
statistically higher degree than did prescription drugs (Appendix 5). This strategymight
be focused on enhancing the apparent safety of the product in the mind of the physician
by reinforcing the message that the OTC product is a well-recognized brand that has been
widely accepted in the marketplace over time.
Disease Identification
A large proportion ofads (71%) identified the disease to be treated and thus, H5 is
not rejected (Appendix 3). However, the fact remains that almost 30% ofproduct ads do
not contain identifiers on what disease or condition the product can be used for.
Therefore, this data might belie assumptions made on the part ofpharmaceutical
companies with regard to the knowledge base ofphysicians. Alternatively, the datamay
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signify a deliberate attempt by the ad to promote
"off-label"
use ofprescription drugs for
conditions other than those approved by the FDA. To investigate these hypotheses,
prescription drug ads were compared to their OTC counterpartswith regard to disease
identification. Prescription drug ads identified the disease in a statistically superior
quantity of the ads (85%, p = 0.0006) versus only 45% for OTC products (Appendix 5).
Thus, it is apparent that any assumption made by the pharmaceutical companies about the
physicians capacity to innately associate a product with a disease is restricted to themore
widely implemented, and presumably safer, OTC products. Moreover, the data indicate a
relative commitment on the part of the pharmaceutical companies to specifically identify
the uses ofprescription products, thus diminishing the potential for "off-label" promotion
to increase revenues. No differences were seen in the identification ofdisease between
new and maintenance products.
Treatment Directives
Related to the hypothesis on disease identification (H5) is whether or not the ad
provides any additional direction on using the drug in terms ofdoses, timing, contra
indications or any other treatment directives. Only 20% ofthe ads described treatment
directives or dosing ofthe product, thus H6 is rejected since less than 50% ofthe ads
contained directives on drug usage. Specifically, 32% of the ads presented dosing
information while only 13% ofads contained other treatment considerations (Appendix
3). Based upon these data, the intent of the pharmaceutical product ad seems clear; to sell
the product on benefits and characteristics first and subsequently follow up with
information on treatment using other forms ofthe promotional mix. Thus the
incorporation of treatment directives in a product ad may be superfluous with no ultimate
impact on the communication to the targeted physician. Moreover, the results presented
in this study are in agreement with an earlier study onDTC prescription ads in which
only minimal information was provided directing the use of the product (22).
Scientific Data
Consistent with providing relevant information to pediatricians is the need to
provide rational evidence in support ofa product's effectiveness in the form of scientific
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data. Resnik and Stem distinguished between independent and company-sponsored
research as sources of such scientific information (13). The current study was unable to
specify the nature ofthe scientific information presented since key identifiers of the data
source were largely not presented in the ads (Appendix 3). However, only 35% of the
ads featured any scientific data whatsoever, and there were no significant differences
between prescription and OTC (Appendix 5) or new versus maintenance products
(Appendix 6). Additionally, only 17% ofads displayed either a chart or graph containing
scientific data in support of the product (Appendix 3). Collectively, these data suggest
that scientific datamay not be as important a tool to validate product benefits as was
assumed, thus H7 is rejected. Scientific data might be thought ofas too complex for
inclusion into themajority ofproduct ads whose primary goal is to generate maximal
impact in a limited time frame.
Ad presentation: the role of emotion
The visual and copy aspects of the ads were investigated in order to illustrate any
patterns in the presentation of the ad, especially with regard to its capacity to induce
emotion in the reader. It is possible that ifpediatricians are exposed to more emotion
rather than rational scientific information, there might be a resultant negative impact on
the delivery ofhealthcare. Thus, one goal of this study was to determinewhether
products ads in the professional print mediawere predominantly educational or
emotional. The inclusion ofemotional informational cues has the capacity to mislead the
prescribing physician on the qualities ofa particular drug by appealing to "gut
instinct"
rather than logic (23). Indeed this may be the raison d'etre ofproduct advertisements
designed by ever more creative advertising agencies. Interestingly, deficiencies in the
educational value have been previously documented for DTC prescription ads (24). In
this study, the emotion contained within the ad was addressed by analysis ofboth images
and text. One of the limitations of this study is that questions regarding emotion are
subject to the interpretation of the reader. Consequently there was a lower level of
agreement (Ir = -0.70) between judges within this category. Nevertheless, the results
were informative since 52% ofads were judged to contain written emotional cues in
either the title or body copy of the ad. No correlation, either positive or negative, was
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seen between the emotional and scientific aspects ofads, thus there is no evidence that
particular ads are biased toward either rational or emotional presentations. Indeed, some
ads (17 and 14% for prescription and OTC, respectively) contained both scientific and
emotional information (Appendix 5). No statistically significant differences were seen in
the emotional content between new and maintenance products (Appendix 6).
It was of interest to note that the increased level of emotion in OTC product ads
approached significance (p = 0.09) relative to prescription drugs (Appendix 5). Taken
togetherwith the result that these ads also preferentially incorporated pictures ofbabies
(50% vs 20% for prescription ads, p = 0.01), the data imply that OTC products
preferentially utilize emotional information cues to stimulate sales rather than the rational
cues favored by prescription drugs (Appendix 5). Similarly, baby photographs were
represented in 38% ofads formaintenance products compared to only 1 1% (p = 0.037) of
new product ads (Appendix 6). Collectively, these data suggest that those products that
have been in the marketplace for longer periods oftime (i.e. are not new and have lost
patent protection) might be forced into the utilization ofemotional messages as a
mechanism to enhance the impact of the ad.
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Discussion and Limitations
The content analysis presented herein attempts to fill the gap in the knowledge of
advertising practices to physicians using the professional print media. The studywas
intentionally focused toward the professional printed media for a variety of reasons:
1 Professional print media occupies a critical position in the communication
process between pharmaceutical company and physician.
2. There has been a recent decline specifically in professional media
expenditures that is inexplicable based upon the documented return on
investment of the printed ad (9).
3. There is a need to balance the literature relative to the abundant information
on direct to consumer advertising.
4. To provide the platform on which product managers can make informed
decisions on the content ofpharmaceutical product advertisements.
The mandate ofany product manager is to increase the sales ofthe product, but in
pharmaceuticals there is also an ethical obligation not to do this at all costs (25). The
pharmaceutical industry is compelled to accurately educate, rather than promote to,
prescribing physicians. In turn, this results in enhanced decision-making by the physician
and consequently effective healthcare solutions for the patient. Therefore, this study
recognizes professional print advertising as an important component of the marketing
plan and provides directives on the content ofprofessional ads.
The data highlight several patterns that pharmaceutical products follow depending
upon their particular classification. Thus, the results provide information and guidance to
product managers with regard to leveraging the professional media in order to create and
sustain a competitive advantage for a particular product. However, it is also recognized
that professional print advertising represents only one component ofthe entire
promotional mix and any decisions should be made in the context of the other
promotional variables ofDTC, medical education and sales force detailing.
The study targeted ads directed toward pediatricians with a view to representing
product advertising to physicians overall. This assumption was made in order to perform
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a manageable study; therefore any resultant conclusion must be placed in the context of
the target audience. Pediatricians are continuously exposed to the heartache of a sick
infant and thus may be more susceptible to emotional cues versus, say, a cardiovascular
surgeon who might be more concerned with product efficacy. Similar studies on specific
medical disciplines are warranted to investigate ifthe conclusions from this study are
pervasive.
This study utilized 3 judges with different levels and types of experience relating
to the medical profession and pharmaceutical industry. While this approach was
beneficial for the efficient assessment ofcontent information, it may not represent the
perspective ofpediatricians, the intended target ofthe ads. However, their individual
experience within the healthcare field combined with the comprehensive training
provided to each judge made them eminently qualified to make informed decisions
regarding the informational content within the ad. Moreover, the extent ofagreement
between the judges seems to affirm any conclusions that were formulated in the pattern of
pharmaceutical advertising to pediatricians presented herein.
Summary
This study has surfaced some profound conclusions relating to the informational
content ofpharmaceutical product ads targeted toward pediatricians:
1 . Pharmaceutical product ads are highly informative relative to consumer ads, and
98% contain details on product characteristics and benefits.
2. For prescription ads, 53% were perceived to favor benefits over risks, rather than
balance such information in accordance with FDAmandates.
3 . Only 71% ofads identified the disease or condition for which the product is used.
Moreover, ads did not typically present treatment or dosing information.
4. Pharmaceutical product ads are biased toward emotional rather than rational
information cues since only 35% ofads contained scientific data whereas 52%
made reference to emotion.
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Appendix 1
14 Information Cues (adapted from Resnik& Stern. 1977)
1 . Product Characteristics: The inherent qualities ofthe product, its components,
durability or engineering.
2. Product Benefits: Product performance, what it does and how well, especially
with reference to any potential competitive advantages.
3. Identify Disease: The disease, syndrome or condition for which the product is
intended.
4. Taste: Evidence presented of superior taste, flavors or texture that could
discriminate from other products.
5. Nutrition: Evidence of the nutritional value of the product, or any reference to
nutritional content.
6. Packaging/Shape: Reference to the package or shape of the product that possibly
confers a competitive advantage.
7. Safety: What safety features pertain to the product. Is the product safe?
8. Independent Research: Is the data presented stated to be from an independent
research organization.
9. Company Research: Is the data presented stated to be from Company sponsored
research efforts?
10. Efficacy/Effectiveness Data: Is the data scientifically relevant, i.e. associated
with thewords
"efficacy"
or
"effectiveness."
11. Scientific Data: Product relevant scientific data presented in any form, e.g.,
graphs or percentages.
12. New/Innovative: The product's position in its lifecycle as described by words
such as "new",
"innovative"
or "coming
soon."
13. Dosing Regimen: Doses ofproduct necessary for treatment. Quantities ofdoses
or number ofdoses per day that could provide differentiation from competitors.
14. Treatment Directives: How to use the drug, when to use the drug, or particular
targeted (or not targeted) groups.
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Appendix 2: Physician Advertisement Content Analysis Questionnaire
Product
Company
Size ofAd Multi-page Full page or less Halfor less
Prescription Yes No
Risk: Benefits (for
prescription ads)
Balanced Risk >50% Benefits >50%
14 information Cues
Product Characteristics Yes No
Product Benefits Yes No
Identify Disease Yes No
Taste Yes No
Nutrition Yes No
Packaging/Shape Yes No
Safety Yes No
Independent Research Yes No Inconclusive
Company Research Yes No Inconclusive
Any Scientific data Yes No
Efficacy data Yes No
New/innovative Yes No
Dosing regimen Yes No
Treatment directives Yes No
Images
Photographic Yes No
Drawing/Cartoon Yes No
Graph/Chart Yes No
Product in Package/vial Yes No
Object Yes No
Animal Yes No
Baby/Infant (< 2 yrs) Yes No
Toddler (2-4 yrs) Yes No
Child (> 4 yrs -18 yrs) Yes No
Parent/Adult (>18yrs) Yes No
Happy Yes No
Suffering Yes No
Neutral Yes No
Copy
Product Benefits in Title Yes No
Product Features in Title Yes No
Emotional Cues in Title Yes No
Product Benefits in Text Yes No
Product Features in Text Yes No
Emotional Cues in Text Yes No
Physician Friendly Yes No
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Appendix 3: Summary ofResults
Size ofAd (%) Multi-page = 0.17 Full page or less = 0.78 Halfor less = 0.05
Prescription (%) Yes = 0.65 No = 0.35
Risk: Benefits (for
prescription ads)
Balanced = 0.47 Risk >50% = 0 Benefits >50% = 0.53
14 information Cues
YES NO Inconclusive Coefficient ofAgreement
Or)
Product Characteristics (%) 0.98 0.02 0.92
Product Benefits (%) 0.94 0.06 0.98
IdentifyDisease (%) 0.71 0.29 0.89
Taste (%) 0.13 0.87 0.98
Nutrition (%) 0.11 0.89 0.95
Packaging/Shape (%) 0.52 0.48 0.78
Safety (%) 0.40 0.60 0.70
Independent Research (%) 0.03 0.05 0.92 0.99
Company Research (%) 0.05 0.04 0.91 0.94
Any Scientific data (%) 0.35 0.65 0.92
Efficacy data (%) 0.25 0.75 0.79
New/innovative (%) 0.29 0.71 0.92
Dosing regimen (%) 0.32 0.68 0.75
Treatment directives (%) 0.13 0.87 0.73
Images
Photographic (%) 0.70 0.30 0.92
Drawing/Cartoon (%) 0.33 0.67 0.87
Graph/Chart (%) 0.17 0.83 0.98
Product in Package/vial (%) 0.54 0.46 1.00
Object (%) 0.22 0.78 0.83
Animal (%) 0.11 0.89 0.98
Baby/Infant (< 2 yrs) (%) 0.30 0.70 0.95
Toddler (2 -4 yrs) (%) 0.14 0.86 0.89
Child(>4y-18y)(%) 0.27 0.73 0.90
Parent/Adult (>18 y) (%) 0.14 0.86 1.00
Happy (%) 0.49 0.51 0.94
Suffering (%) 0.11 0.89 0.97
Neutral (%) 0.17 0.83 0.92
Copy
Product Benefits in Title (%) 0.81 0.19 0.81
Product Features in Title (%) 0.51 0.49 0.81
Emotional Cues in Title (%) 0.40 0.60 0.72
Product Benefits in Text (%) 0.89 0.11 0.89
Product Features in Text (%) 0.94 0.06 0.87
Emotional Cues in Text (%) 0.32 0.68 0.67
Physician Friendly (%) 0.73 0.27 0.88
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Appendix 4
Frequency of ads across journal and over time
Journal Jan Feb Mar Apr May June Total (%)
Archives ofPediatrics
and Adolescent Medicine
5 5 5 5 3 3 26(6)
Infectious Diseases of
Children
24 32 36 40 36 27 195 (47)
Pediatrics 7 6 9 6 6 5 39 (10)
Pediatric News 19 23 21 25 24 17 129 (31)
Pediatric Research 1 1 1 2 1 1 7(2)
Pediatric Infectious
Disease Journal
3 3 3 3 1 2 15(4)
Total (%) 59(15) 70 (17) 75 (18) 81 (20) 71(17) 55 (13) 411 (100)
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Appendix 5
A Comparison ofPrescription versus OTC Products
Prescription OTC
Information Cues (avg #jper ad) 5.1 (p = 0.10) 5.2
Disease (%) 0.85 (p = 0.0006) 0.45
Packaging (%) 0.34 0.86 (p = 0.00003)
ScientificData (%) 0.37 (p > 0.05) 0.32
Vial Shown (%) 0.34 0.90 (p = 0.000004)
Baby Picture (%) 0.20 0.50 (p = 0.01)
Emotion (%) 0.24 0.45 (p = 0.09)
Scientific Data + Emotion (%) 0.17 (p> 0.05) 0.14
*Statistical analyses performed by one-way analysis ofvariance (ANOVA) wherein
significancewas established using a i value = 0.05.
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Appendix 6
New products versus Maintenance products
New Maintenance
Information Cues (avg # per ad) 6.1 (p = 0.0049) 4.7
Safety (%) 0.50 (p > 0.05) 0.36
Scientific Data (%) 0.33 0.36 (p > 0.05)
Baby Picture (%) 0.11 0.38 (p = 0.037)
Suffering (%) 0 0. 16 (p = 0.078)
Emotion (%) 0.29 0.43 (p > 0.05)
*Statistical analyses performed by one-way analysis ofvariance (ANOVA) wherein
significance was established using a f value = 0.05.
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